Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property Routine +

Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders

Psyence Shareholders Approve GoldCoast Amalgamation; CSE Approval Remains Key Hurdle

By The Northwire Desk — AI Analysis May 21, 2026 · 19:00 PSYG · 0.12 Psyence Group Inc.
Executive Summary
  • The most recent release (May 21, 2026) confirms shareholders approved the amalgamation between Psyence Group Inc. and GoldCoast Resource Corp.
  • Shareholders also approved a name change to "GoldCoast Resource Corp." and a share consolidation resolution.
  • This follows a series of prior announcements starting November 2025 regarding the proposed Reverse Takeover (RTO).
  • Financing conditions were met in March and April 2026 with $8.6M USD raised via private placements at $0.85 per share for GoldCoast.
  • The transaction transitions the company from a biotechnology issuer to an offshore gold exploration issuer focused on Ghana's continental shelf.
  • Completion remains subject to Canadian Securities Exchange (CSE) approval and other regulatory consents.
Material Impact
  • Procedural Milestone: Shareholder approval is a necessary condition precedent but was largely anticipated given the financing rounds completed in Q1 2026.
  • Valuation Shift: The deal fundamentally alters the asset base from biotech to mining, which typically commands different valuation multiples, though the current price ($0.12) suggests skepticism regarding the offshore gold assets.
  • Regulatory Risk: Despite shareholder approval, CSE listing approval is still pending ("subject to CSE approval"). This remains a significant binary risk; rejection would terminate the transaction and potentially force liquidation or loan repayment.
  • Market Pricing: The stock price remained stagnant at $0.12 throughout the financing and amendment period (Jan 2026 - May 2026), indicating the market did not view these milestones as value-accretive surprises.
  • Consolidation Risk: A share consolidation is approved but the ratio is undetermined ("final ratio to be determined by the board"). This creates uncertainty regarding post-closing liquidity and float.
PSYG · Price
Company Overview
  • Current Entity: Psyence Group Inc., transitioning to GoldCoast Resource Corp.
  • Flagship Project: Offshore gold exploration on Ghana's shallow continental shelf (Western offshore).
  • Asset Base: Ten contiguous reconnaissance licenses covering approximately 10,000 km² granted in January 2026.
  • Development Stage: Reconnaissance phase; requires further evaluation to progress to prospecting or mining licenses.
  • Business Model: Transition from biotechnology development (Psyence Therapeutics) to natural resource exploration and potential extraction.
Read the original news release →

More from Psyence Group Inc.

Apr 23, 2026 · 18:30

Psyence Advances GoldCoast Merger Amidst Trading Halt; Shareholder Vote Set for May

M&A / Property Mar 25, 2026 · 04:31

Psyence Advances RTO with GoldCoast as $8.6M Financing Clears Key Hurdle

Financings Mar 17, 2026 · 23:15

Psyence target GoldCoast closes $5.82-million financing

Financings Mar 17, 2026 · 19:00

Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.

Financings Feb 24, 2026 · 06:00

Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.

Other Jan 27, 2026 · 18:34

Psyence RTO target receives reconnaissance licences

M&A / Property